1,7-dioxa-4,7,8,9-tetrahydroindan | 412320-67-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 呋喃吡喃类
• 英文名称: 1,7-dioxa-4,7,8,9-tetrahydroindan
• 英文别名: 3,3a,4,7a-tetrahydro-2H-furo[2,3-b]pyran
• CAS: 412320-67-3
• 化学式: C₇H₁₀O₂
• 分子量: 126.155
• InChiKey: HHUZBGHAFHPXFF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  18.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1,7-dioxa-4,7,8,9-tetrahydroindan 在 盐酸 、 乙醇 、 镍 作用下， 20.0 ℃ 、8.83 MPa 条件下， 生成 (+/-)-3-hydroxymethyl-hexane-1,6-diol
  参考文献：
  名称：

  Paul; Tchelitcheff, Bulletin de la Societe Chimique de France, 1954, p. 672,674

  摘要：

  DOI：
• 作为产物：
  描述：

  2,3-二氢呋喃 、 丙烯醛 生成 1,7-dioxa-4,7,8,9-tetrahydroindan
  参考文献：
  名称：

  Paul; Tchelitcheff, Bulletin de la Societe Chimique de France, 1954, p. 672,674

  摘要：

  DOI：

文献信息

• [EN] (--)- HUPERZINE A PROCESSES AND RELATED COMPOSITIONS AND METHODS OF TREATMENT<br/>[FR] PROCÉDÉS DE FABRICATION DE (-) HUPERZINE A, COMPOSITIONS ASSOCIÉES, ET MÉTHODES DE TRAITEMENT
  申请人：UNIV YALE

  公开号：WO2012121863A1

  公开（公告）日：2012-09-13

  The invention provides (1) processes for making substantially-pure (-) huperzine A and substantially-pure (-) huperzine A derivatives; (2) compositions useful in making substantially-pure (-) huperzine A and substantially-pure (-) huperzine A derivatives; and (3) methods of treating or preventing neurological disorders using substantially-pure (-) huperzine A and substantially-pure (-) huperzine A derivatives.

  该发明提供了三个方面：(1) 制备几乎纯的(-)华佩嗪A和几乎纯的(-)华佩嗪A衍生物的过程；(2) 用于制备几乎纯的(-)华佩嗪A和几乎纯的(-)华佩嗪A衍生物的组合物；以及(3) 使用几乎纯的(-)华佩嗪A和几乎纯的(-)华佩嗪A衍生物治疗或预防神经系统疾病的方法。
• Rab7 GTPase Inhibitors and Related Methods of Treatment
  申请人：Wandinger-Ness Angela

  公开号：US20140248268A1

  公开（公告）日：2014-09-04

  This invention relates to compounds and their use as inhibitors or activators of Rab7 GTPase to treat or prevent the onset of Rab 7 GTPase-associated disorders such as neuropathies, cancer, metabolic diseases of bone and lipid storage. The invention is also applicable to infectious diseases where Rab7 is inactivated or its protein-protein interactions are modulated to facilitate intracellular survival of pathogens. The compound described acts as a competitive inhibitor of nucleotide binding and as such also has utility as a scaffold for targeting other small GTPases. In one aspect, methods of treatment of the invention are used to treat or prevent the onset of hereditary sensory neuropathies such as Charcot-Marie-Tooth type 2B disease. Related pharmaceutical compositions, assays, and drug screens are also provided.

  本发明涉及化合物及其作为Rab7 GTP酶抑制剂或激活剂的用途，以治疗或预防Rab 7 GTP酶相关疾病，如神经病变、癌症、骨代谢疾病和脂质储存病。该发明还适用于Rab7被失活或其蛋白质-蛋白质相互作用被调节以促进病原体的细胞内生存的感染性疾病。所述化合物作为核苷酸结合的竞争性抑制剂，并且也具有作为靶向其他小GTP酶的支架的效用。在一个方面，本发明的治疗方法用于治疗或预防遗传性感觉神经病变，如Charcot-Marie-Tooth 2B病。还提供相关的制药组合物、测定和药物筛选。
• INTERMEDIATE COMPOUNDS UTILIZABLE IN SYNTHESIS OF (-) HUPERZINE AND PROCESS FOR OBTAIN ONE OF THESE INTERMEDIATE COMPOUNDS
  申请人：Yale University

  公开号：EP3434669A1

  公开（公告）日：2019-01-30

  The invention provides Intermediate compounds utilizable in synthesis of (-)-Huperzine and process for obtain one of these intermediate compounds.

  本发明提供了可用于合成 (-)-Huperzine 的中间体化合物以及获得这些中间体化合物之一的工艺。
• (−)-Huperzine A processes and related compositions and methods of treatment
  申请人：Herzon Seth

  公开号：US10059672B2

  公开（公告）日：2018-08-28

  The invention provides (1) processes for making substantially-pure (−) huperzine A and substantially-pure (−) huperzine A derivatives; (2) compositions useful in making substantially-pure (−) huperzine A and substantially-pure (−) huperzine A derivatives; and (3) methods of treating or preventing neurological disorders using substantially-pure (−) huperzine A and substantially-pure (−) huperzine A derivatives.

  本发明提供了（1）制造实质上纯净的（-）虎佩嗪 A 和实质上纯净的（-）虎佩嗪 A 衍生物的工艺；（2）用于制造实质上纯净的（-）虎佩嗪 A 和实质上纯净的（-）虎佩嗪 A 衍生物的组合物；以及（3）使用实质上纯净的（-）虎佩嗪 A 和实质上纯净的（-）虎佩嗪 A 衍生物治疗或预防神经系统疾病的方法。
• (−)-huperzine A processes and related compositions and methods of treatment
  申请人：Yale University

  公开号：US10457643B2

  公开（公告）日：2019-10-29

  The invention provides (1) processes for making substantially-pure (−) huperzine A and substantially-pure (−) huperzine A derivatives; (2) compositions useful in making substantially-pure (−) huperzine A and substantially-pure (−) huperzine A derivatives; and (3) methods of treating or preventing neurological disorders using substantially-pure (−) huperzine A and substantially-pure (−) huperzine A derivatives.

  本发明提供了（1）制造实质上纯净的（-）虎佩嗪 A 和实质上纯净的（-）虎佩嗪 A 衍生物的工艺；（2）用于制造实质上纯净的（-）虎佩嗪 A 和实质上纯净的（-）虎佩嗪 A 衍生物的组合物；以及（3）使用实质上纯净的（-）虎佩嗪 A 和实质上纯净的（-）虎佩嗪 A 衍生物治疗或预防神经系统疾病的方法。